Vericel (NASDAQ:VCEL) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Vericel (NASDAQ:VCEL) from a hold rating to a buy rating in a research note issued to investors on Saturday morning.

VCEL has been the topic of a number of other reports. Truist Financial cut their price target on shares of Vericel from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Thursday, December 18th. HC Wainwright raised their price objective on shares of Vericel from $60.00 to $64.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Leerink Partners reaffirmed an “outperform” rating and issued a $46.00 price objective on shares of Vericel in a research report on Tuesday, March 10th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Vericel in a research note on Monday, December 29th. Five analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $56.00.

Vericel Trading Up 4.1%

Shares of VCEL opened at $30.55 on Friday. The company has a market capitalization of $1.56 billion, a price-to-earnings ratio of 98.55 and a beta of 1.22. The stock has a 50 day moving average of $35.04 and a 200 day moving average of $35.77. Vericel has a 12 month low of $28.95 and a 12 month high of $45.97.

Vericel (NASDAQ:VCEL) last posted its quarterly earnings data on Thursday, February 26th. The biotechnology company reported $0.45 earnings per share for the quarter, hitting the consensus estimate of $0.45. The business had revenue of $92.92 million for the quarter, compared to analysts’ expectations of $92.66 million. Vericel had a return on equity of 5.17% and a net margin of 5.98%.The business’s revenue was up 23.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.38 earnings per share. As a group, equities research analysts predict that Vericel will post 0.14 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in VCEL. Hsbc Holdings PLC purchased a new stake in Vericel in the 4th quarter worth about $300,000. Rockefeller Capital Management L.P. lifted its holdings in Vericel by 30.7% during the fourth quarter. Rockefeller Capital Management L.P. now owns 13,025 shares of the biotechnology company’s stock valued at $469,000 after purchasing an additional 3,057 shares during the last quarter. Empowered Funds LLC purchased a new stake in Vericel during the fourth quarter valued at about $58,000. XTX Topco Ltd bought a new position in Vericel during the fourth quarter worth about $668,000. Finally, Susquehanna Portfolio Strategies LLC boosted its position in Vericel by 43.5% during the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 135,054 shares of the biotechnology company’s stock worth $4,863,000 after purchasing an additional 40,948 shares during the period.

Vericel Company Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.